ICM
SUPN icon

Islay Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Islay Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,065
Closed -$73K – 306
2020
Q1 		$73K Buy
4,065
+1,422
+54% +$29.9K 0.1% 119
2019
Q4 		$63K Buy
+2,643
New +$64.2K 0.06% 158

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Islay Capital Management's SUPN Position: Q2 2020 in Review

Islay Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2020, closing a stake of 4,065 shares — an estimated $73K sold.

Islay Capital Management first reported a position in SUPN in Q4 2019 and held it in 2 quarters. The position peaked at $73K in Q1 2020. 218 funds tracked by Wall St. Rank hold SUPN as of Q2 2020.

  • Islay Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Islay Capital Management sold 4,065 Supernus Pharmaceuticals shares in Q2 2020, an estimated $73K.
  • Islay Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Islay Capital Management's Supernus Pharmaceuticals position peaked at $73K in Q1 2020.
  • 218 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2020.

Based on Islay Capital Management's 13F filing for Q2 2020, filed 4 Aug 2020.